公开(公告)号：US20070186295A1

公开(公告)日：2007-08-09

申请号：US11657313

申请日：2007-01-24

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  A61K39/00 ,  A61K48/00 ,  C07K14/82 ,  C07K16/30

CPC分类号： C07K16/32 ,  A61K39/0011 ,  C07K14/4748 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  G01N33/57423 ,  G01N33/57492 ,  G01N33/6884

摘要： Surprisingly, the present inventors have discovered that expression of TAT-036 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-036 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-036 expression or activity, comprising: contacting a candidate compound with a TAT-036 and detecting the presence or absence of binding between said compound and said TAT-036, or detecting a change in TAT-036 expression or activity. Methods are also included for the identification of compounds that modulate TAT-036 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-036 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-036蛋白的表达与癌相关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-036与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-036表达或活性的化合物的方法，其包括：使候选化合物与TAT-036接触并检测所述化合物与所述TAT-036之间是否存在结合，或 检测TAT-036表达或活性的变化。 还包括用于鉴定调节TAT-036表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-036表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070269434A1

公开(公告)日：2007-11-22

申请号：US11700378

申请日：2007-01-31

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A61K39/395 ,  A61K48/00 ,  C07H21/00 ,  C07K16/18 ,  C12N5/06 ,  C12Q1/68 ,  G01N33/53

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136

摘要： Surprisingly, the present inventors have discovered that expression of TAT-041 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-041 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-041 expression or activity, comprising: contacting a candidate compound with a TAT-041 and detecting the presence or absence of binding between said compound and said TAT-041, or detecting a change in TAT-041 expression or activity. Methods are also included for the identification of compounds that modulate TAT-041 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-041 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-041蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-041与异常发育和生长相关，并且可用作鉴定抗癌化合物（包括用于免疫治疗的抗体）的靶标。 因此，本发明提供了用于鉴定抑制TAT-041表达或活性的化合物的方法，其包括：使候选化合物与TAT-041接触并检测所述化合物与所述TAT-041之间是否存在结合，或 检测TAT-041表达或活性的变化。 还包括用于鉴定调节TAT-041表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-041表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070192886A1

公开(公告)日：2007-08-16

申请号：US11699785

申请日：2007-01-30

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  G01N33/574 ,  C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  A61K39/00 ,  A61K48/00

CPC分类号： G01N33/57423 ,  A61K39/00 ,  C07K14/4748 ,  C07K16/32 ,  G01N2500/00

摘要： Surprisingly, the present inventors have discovered that expression of TAT-044 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-044 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-044 expression or activity, comprising: contacting a candidate compound with a TAT-044 and detecting the presence or absence of binding between said compound and said TAT-044, or detecting a change in TAT-044 expression or activity. Methods are also included for the identification of compounds that modulate TAT-044 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-044 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-044蛋白的表达与癌症相关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-044与异常发育和生长有关，可用作鉴定抗癌化合物（包括用于免疫治疗的抗体）的靶标。 因此，本发明提供了用于鉴定抑制TAT-044表达或活性的化合物的方法，其包括：使候选化合物与TAT-044接触并检测所述化合物与所述TAT-044之间是否存在结合，或 检测TAT-044表达或活性的变化。 还包括用于鉴定调节TAT-044表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-044表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070220620A1

公开(公告)日：2007-09-20

申请号：US11700590

申请日：2007-01-31

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  A61K48/00 ,  C07K16/30 ,  C07K14/82 ,  C12P21/06

CPC分类号： G01N33/57423 ,  A61K39/00 ,  C07K14/4748 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/73 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136

摘要： Surprisingly, the present inventors have discovered that expression of TAT-046 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-046 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-046 expression or activity, comprising: contacting a candidate compound with a TAT-046 and detecting the presence or absence of binding between said compound and said TAT-046, or detecting a change in TAT-046 expression or activity. Methods are also included for the identification of compounds that modulate TAT-046 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-046 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现，人类患者中TAT-046蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-046与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-046表达或活性的化合物的方法，包括：使候选化合物与TAT-046接触并检测所述化合物与所述TAT-046之间是否存在结合，或 检测TAT-046表达或活性的变化。 还包括用于鉴定调节TAT-046表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-046表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070192885A1

公开(公告)日：2007-08-16

申请号：US11698734

申请日：2007-01-26

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  C12P21/06 ,  C07K14/82 ,  C07K16/30 ,  A61K39/00

CPC分类号： G01N33/574 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/156 ,  G01N33/57423 ,  G01N2500/00

摘要： Surprisingly, the present inventors have discovered that expression of TAT-039 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-039 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-039 expression or activity, comprising: contacting a candidate compound with a TAT-039 and detecting the presence or absence of binding between said compound and said TAT-039, or detecting a change in TAT-039 expression or activity. Methods are also included for the identification of compounds that modulate TAT-039 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-039 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-039蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-039与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了鉴定抑制TAT-039表达或活性的化合物的方法，包括：使候选化合物与TAT-039接触，并检测所述化合物与所述TAT-039之间是否存在结合，或 检测TAT-039表达或活性的变化。 还包括用于鉴定调节TAT-039表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-039表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070192884A1

公开(公告)日：2007-08-16

申请号：US11698245

申请日：2007-01-25

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  A61K39/395 ,  A61K39/00 ,  C07K14/82 ,  C07K16/30 ,  A61K48/00

CPC分类号： G01N33/57423 ,  C07K14/4748 ,  C07K16/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/57492 ,  G01N2500/00

摘要： Surprisingly, the present inventors have discovered that expression of TAT-038 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-038 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-038 expression or activity, comprising: contacting a candidate compound with a TAT-038 and detecting the presence or absence of binding between said compound and said TAT-038, or detecting a change in TAT-038 expression or activity. Methods are also included for the identification of compounds that modulate TAT-038 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-038 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人吃惊的是，本发明人已经发现，人类患者中TAT-038蛋白的表达与癌相关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-038与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了鉴定抑制TAT-038表达或活性的化合物的方法，其包括：使候选化合物与TAT-038接触并检测所述化合物与所述TAT-038之间是否存在结合，或 检测TAT-038表达或活性的变化。 还包括用于鉴定调节TAT-038表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-038表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070180545A1

公开(公告)日：2007-08-02

申请号：US11655859

申请日：2007-01-19

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  A61K48/00 ,  C12P21/06 ,  A61K39/395 ,  A61K39/00

CPC分类号： G01N33/57423 ,  A61K39/00 ,  A61K2039/505 ,  C07K16/3023 ,  C07K2317/34 ,  C07K2317/73 ,  G01N2500/00

摘要： Surprisingly, the present inventors have discovered that expression of TAT-031 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-031 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-031 expression or activity, comprising: contacting a candidate compound with a TAT-031 and detecting the presence or absence of binding between said compound and said TAT-031, or detecting a change in TAT-031 expression or activity. Methods are also included for the identification of compounds that modulate TAT-031 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-031 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-031蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-031与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了鉴定抑制TAT-031表达或活性的化合物的方法，包括：使候选化合物与TAT-031接触，并检测所述化合物与所述TAT-031之间是否存在结合，或 检测TAT-031表达或活性的变化。 还包括用于鉴定调节TAT-031表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，以及检测TAT-031表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070192887A1

公开(公告)日：2007-08-16

申请号：US11699833

申请日：2007-01-30

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/04 ,  A61K39/395 ,  A61K39/00 ,  C07K14/82 ,  C07K16/30 ,  A61K48/00

CPC分类号： C07K14/4748 ,  C07K14/705 ,  G01N33/57423

摘要： Surprisingly, the present inventors have discovered that expression of TAT-042 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-042 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-042 expression or activity, comprising: contacting a candidate compound with a TAT-042 and detecting the presence or absence of binding between said compound and said TAT-042, or detecting a change in TAT-042 expression or activity. Methods are also included for the identification of compounds that modulate TAT-042 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-042 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-042蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-042与异常发育和生长相关，并且可用作鉴定抗癌化合物（包括用于免疫治疗的抗体）的靶标。 因此，本发明提供了鉴定抑制TAT-042表达或活性的化合物的方法，包括：使候选化合物与TAT-042接触，并检测所述化合物与所述TAT-042之间是否存在结合，或 检测TAT-042表达或活性的变化。 还包括用于鉴定调节TAT-042表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-042表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070192883A1

公开(公告)日：2007-08-16

申请号：US11655858

申请日：2007-01-19

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  A61K39/395 ,  A61K48/00 ,  A61K39/00 ,  C07K14/82 ,  C07K16/30

CPC分类号： G01N33/57423 ,  A01K2217/05 ,  A61K2039/505 ,  C07K14/4748 ,  C07K16/30 ,  C07K2317/34 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N33/57492 ,  G01N2500/00

摘要： Surprisingly, the present inventors have discovered that expression of TAT-028 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-028 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-028 expression or activity, comprising: contacting a candidate compound with a TAT-028 and detecting the presence or absence of binding between said compound and said TAT-028, or detecting a change in TAT-028 expression or activity. Methods are also included for the identification of compounds that modulate TAT-028 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-028 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-028蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-028与异常发育和生长相关，并且可用作鉴定抗癌化合物（包括用于免疫治疗的抗体）的靶标。 因此，本发明提供了用于鉴定抑制TAT-028表达或活性的化合物的方法，包括：使候选化合物与TAT-028接触并检测所述化合物与所述TAT-028之间是否存在结合，或 检测TAT-028表达或活性的变化。 还包括用于鉴定调节TAT-028表达或活性的化合物的方法，包括：向细胞或细胞群体施用化合物，以及检测TAT-028表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。

公开(公告)号：US20070186294A1

公开(公告)日：2007-08-09

申请号：US11656316

申请日：2007-01-19

申请人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

发明人： Daniel Chelsky ,  Paul Kearney ,  Eustache Paramithiotis ,  Lyes Hamaidi ,  Leslie Kondejewski ,  Joel Lanoix ,  Patrice Hugo

IPC分类号： A01K67/027 ,  C12Q1/68 ,  G01N33/574 ,  A61K39/00 ,  A61K48/00 ,  C07K14/82 ,  C07K16/30

CPC分类号： C07K16/3023 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/4748 ,  C07K2317/73 ,  C12N5/0018 ,  C12N2500/32 ,  C12N2500/34 ,  C12N2500/38 ,  C12N2500/74 ,  C12N2500/76 ,  C12N2510/02 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/57423 ,  G01N33/57492

摘要： Surprisingly, the present inventors have discovered that expression of TAT-030 protein in human patients is associated with cancer, and that the overexpressed protein is present in plasma membrane fractions. Thus, the present inventors have discovered that TAT-030 is associated with abnormal development and growth, and may be useful as a target for the identification of anti-cancer compounds, including antibodies for use in immunotherapy. Accordingly, the present invention provides methods for the identification of compounds that inhibit TAT-030 expression or activity, comprising: contacting a candidate compound with a TAT-030 and detecting the presence or absence of binding between said compound and said TAT-030, or detecting a change in TAT-030 expression or activity. Methods are also included for the identification of compounds that modulate TAT-030 expression or activity, comprising: administering a compound to a cell or cell population, and detecting a change in TAT-030 expression or activity. The methods of the invention are useful for the identification of anti-cancer compounds.

摘要翻译： 令人惊奇的是，本发明人已经发现人类患者中TAT-030蛋白的表达与癌症有关，并且过表达的蛋白质存在于质膜组分中。 因此，本发明人已经发现，TAT-030与异常发育和生长相关，并且可用作鉴定抗癌化合物的靶标，包括用于免疫治疗的抗体。 因此，本发明提供了用于鉴定抑制TAT-030表达或活性的化合物的方法，包括：使候选化合物与TAT-030接触并检测所述化合物与所述TAT-030之间是否存在结合，或 检测TAT-030表达或活性的变化。 还包括用于鉴定调节TAT-030表达或活性的化合物的方法，包括：向细胞或细胞群施用化合物，并检测TAT-030表达或活性的变化。 本发明的方法可用于鉴定抗癌化合物。